Recruiting PHASE4 INTERVENTIONAL 2-arm NCT06108414

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

The Efficacy and Safety of Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Sponsor: China National Center for Cardiovascular Diseases

Conditions Anticoagulant Adverse Reaction Atrial Fibrillation Major Adverse Cardiac Events Stroke

Interventions Standard-dose rivaroxaban low-dose rivaroxaban

Updated 6 times since 2023 Last updated: Sep 11, 2024 Started: Sep 1, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Anticoagulant Adverse Reaction and Atrial Fibrillation and is currently actively recruiting participants. China National Center for Cardiovascular Diseases leads this study, which shows 6 recorded versions since 2024 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Oct 2024 — Present [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE4
Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE4
Jul 2024 — Aug 2024 [monthly]

Not Yet Recruiting PHASE4
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE4

▶ Show 1 earlier version

Nov 2023 — Jun 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

China National Center for Cardiovascular Diseases

Data source: China National Center for Cardiovascular Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China